argenx sells $1bn of stock

© 2025 GlobalCapital, Derivia Intelligence Limited, company number 15235970, 4 Bouverie Street, London, EC4Y 8AX. Part of the Delinian group. All rights reserved.

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement | Event Participant Terms & Conditions

Cookies Settings
Equity
ABBs-Block Trades

argenx sells $1bn of stock

Aidan Gregory
February 03, 2021 11:00 am
argenx_PA_575_375
Illustration picture shows the bell ceremony for the new Bel20 company Argenx at the NYSE Euronext Brussels Stock Exchange, in Brussels, Friday 15 June 2018. BELGA PHOTO NICOLAS MAETERLINCK | NICOLAS MAETERLINCK/PA Images

Dutch biotech firm argenx has tapped equity investors for $1bn (€830.3m) to finance research and development.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Request a Free Trial or Login

Topics

The NetherlandsEquityABBs-Block TradesEuropeEMEA
AG
Aidan Gregory
Gift this article